

Lightning talk abstracts

Precision and mechanistic oncology

[Winner: Best lightning talk] Unveiling the heterogeneity of pancreatic cancer initiation: a novel perspective on epithelial-immune cell-cell Interactions

Ella Reed¹, Reuben Asher², Pilar Acedo Nunez², Catherine Hogan¹ and Beatriz Salvador-Barbero¹

1. ECSCRI, School of Biosciences, Cardiff University, Cardiff, UK
2. UCL Institute for Liver and Digestive Health, London, UK

Immuno-oncology

Targeting Ovarian Cancer and Its Microenvironment: A Novel Synergistic Approach Combining RAGE-Directed Antibody-Drug Conjugate and Prokineticin-2

Mélanie Boudaud^{1,2,3}, Constance Collet^{2,3}, Frédéric Sergent^{2,3}, Alizée Jacquard^{2,3}, Nicolas Lemaître^{2,3}, Sara Karroum^{2,3}, Mohamed Benharouga^{2,3}, Deya Gonzalez¹, Nadia Alfaidy^{2,3}, Steve Conlan¹

1. Reproductive Biology and Gynaecological Oncology (RBGO), Swansea University Medical School
2. Commissariat à l'Energie Atomique (CEA)
3. UMR 1292 INSERM/CEA/UGA, Mechanism of Angiogenesis in Biological Barriers (MAB2), Biology and Biotechnology for Health Laboratory (IRIG)

Radiotherapy

Microstructural imaging of Glioblastoma tumours using ultra-strong gradient and multi-dimensional diffusion MRI

Muhammad Usman Akbar^{1,2}, Michael Law¹, Jennifer Golten^{1,3}, Najmus Sahar Iqbal³, Elise Gwyther⁴, George Eralil³, Harpreet Hyare⁵, Hannah Khirwadkar⁶, Kathy Seddon⁷, Matteo Figini⁸, Eleftheria Panagiotaki⁸, Florian Siebzehrnubel⁹, Sarah Jones¹, Tara Davies¹, Derek Jones¹, James Powell³, Marco Palombo^{1,2}

1. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom
2. School of Computer Science and Informatics, Cardiff University, Cardiff, United Kingdom
3. Velindre cancer centre, Velindre Rd, CF14 2TL, Cardiff, United Kingdom
4. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff, United Kingdom
5. Department of Translational Neuroscience and Stroke, UCL Queen Square Institute of Neurology, University College London, London, UK
6. Swansea Bay University Health Board, Morriston Hospital, United Kingdom
7. Public and Patient Representative, Wales Cancer Research Centre, United Kingdom
8. Hawkes Institute, Department of Computer Science, University College London, London, United Kingdom
9. European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom

Cancer clinical trials

Baseline symptom burden and quality of life in newly diagnosed myeloid malignancies: Results from the international PROACTIVE project

Sean Johnson¹, Fabio Efficace², Adriano Venditti³, Thomas Baldi², Joanna Canham¹, Abin Thomas¹, Giovanni Martinelli⁴, Alfonso Piciocchi², Mike Dennis⁵, Steve Knapper⁶, Nigel H Russell⁷, Maria Teresa Voso³, Marco Vignetti², Ian Thomas¹

1. Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
2. Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
3. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
4. IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l, Meldola, Italy.
5. The Christie NHS Foundation Trust, Manchester, United Kingdom
6. School of Medicine, Cardiff University, Cardiff, United Kingdom

Department of Haematology, Nottingham University Hospital, Nottingham, UK

Palliative and supportive oncology

The Feasibility of Inclusive Prehabilitation (I-Prehab) Education for Cancer Care Workers

Nichola Gale¹, Alexandra Mitchell¹, Akhilesh Ramachandran¹, Manasi Patil¹, Sally Wheelright², Jane Hopkinson¹, Shea Palmer¹

1. School of Healthcare Sciences, Cardiff University
2. Brighton and Sussex Medical School, University of Sussex

Population health-based cancer prevention, detection, primary care and health service research

Preparing healthcare providers and policy makers for equitable and informed implementation of Multi-Cancer Early Detection (MCED) blood tests

Harriet Quinn-Scoggins¹, Delyth Price¹, Uju Ogbonna², Richard Adams³, Rikke Andersen⁴, Julie Hepburn⁵, Rashmi Kumar⁵, Laura Marlow⁶, Fiona Wood¹, Kate Brain¹

1. PRIME Centre Wales, Division of Population Medicine, Cardiff University
2. Division of Population Medicine, Cardiff University
3. Centre for Trials Research, Cardiff University
4. Department of Public Health, Research Unit of General Practice, University of Southern Denmark
5. Lay Representative
6. Centre for Cancer Prevention, Screening and Early Diagnosis, Queen Mary University of London

Poster abstracts

Precision and mechanistic oncology

Targeting FZD7/Wnt Signalling to Treat Metastatic Prostate Cancer

Kieran Hodson¹, Jessica Hembrough¹, Sarah Koushyar¹, Hector Arrendondo¹, Valerie Meniel¹, Helen Pearson¹, Karl Willert², Toby Phesse¹

1. The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff CF24 4HQ, UK
2. School of Medicine, University California San Diego, La Jolla, CA 92093, USA

Understanding the functional importance of the Wnt receptor FZD7 in prostate tumourigenesis.

Jess Hembrough¹, Kieran Hodson¹, Anna Richards¹, Karl Willert², Helen Pearson¹, Toby Phesse¹

1. The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff CF24 4HQ, UK
2. School of Medicine, University California San Diego, La Jolla, CA 92093, USA

Automated Spatial Phenotyping of Fibroblasts in Prostate Cancer: Unlocking Predictive Insights

Anna E Richards¹, Leah Officer-Jones², Silvia Martinelli², Lisa Spary³, Rachel L Baird², John Le Quesne², Helen B Pearson¹

1. The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff, UK
2. Cancer Research UK Scotland Institute (CRUK SI), Glasgow, UK
3. Wales Cancer Bank, University Hospital Wales, Cardiff, UK

BCL3: a promising therapeutic target to treat prostate cancer

Tabitha Cunliffe¹, Marcos Quintela-Vazquez¹, Daniel J. Turnham¹, Boris Shorning¹, Luke Piggott², Robert Jones³, Andrea Brancale⁴, Andrew Westwell⁵, Richard W.E. Clarkson¹ and Helen B. Pearson¹

1. ECSCRI, School of Biosciences, Cardiff University
2. TNA Therapeutics, USA
3. ECMC Cardiff, University Hospital Wales, Cardiff University
4. University of Chemistry and Technology, Prague
5. School of Pharmacy, Cardiff University

Investigating the role of P-REX2 in prostate cancer

Samuel C. Hawkins¹, Boris S. Shorning¹, Wytske Van Weerden², Heidi C.E. Welch³, Richard W.E. Clarkson¹, Andrew D. Campbell⁴ and Helen B. Pearson¹

1. The European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, UK
2. ERASMUS Medical University, Rotterdam.
3. Babraham Institute, Cambridge University, Cambridge, UK
4. Cancer Research UK Scotland Institute, Glasgow, UK

Exploring the mechanism and predictability of KRASG12D cell elimination mechanisms in the adult pancreas.

Non Williams¹, Beatriz Salvador-Barbero¹, Angela Marchbank², Maria Secrier³, and Catherine Hogan¹

1. European Cancer Stem Cell Research Institute, Cardiff University
2. Genome & Research Hub, Cardiff University
3. UCL Genetics Institute, University College London

Virus directed enzyme prodrug cancer gene therapy using the conversion of ethanol to acetaldehyde via enhanced ADH activity, supported by inhibition of ALDH and drugs that inhibit DNA damage repair.

Emily Proudman¹, Audrey Clooney¹, Rebecca Bayliss¹, Alan Parker¹, Philip Savage¹

1. Cardiff University

Quizartinib Exposure Drives Resistance to Multiple Kinase Inhibitors and Reversal of FLT3 Internal Tandem Duplication in Acute Myeloid Leukaemia.

James A. Austin¹, Giusy Russomanno², Dominic P. Byrne³, John A Harris³, Muhammad Ameer Saif⁴, David J. MacEwan², Patrick A Eyers³ and Vanessa Marensi^{3,5}

1. Department of Clinical Infection, Microbiology & Immunology, Institute of Infection, Veterinary & Ecological Sciences Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
2. Department of Pharmacology & Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
3. Department of Biochemistry, Cell & Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
4. The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK
5. North West Cancer Research Institute, North Wales Medical School, Bangor University, Wales, UK

ATRX loss alters telomere fusion complexity and structure

Lexie Hall¹, Kez Cleal¹, Greg Ngo¹, Duncan Baird¹

1. Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN

Long-read Sequencing in Circulating Tumour DNA (ctDNA) Lung Cancer Liquid Biopsies

Karam Aboud^{1,2}, Sian Morgan², Rachel Dodds², Joanne Morgan¹, Nigel Williams¹, Andrew Beggs⁶, Nick Tovey⁶, Joanne Stockton⁶, Rob Jones¹, Paul Shaw⁴, Richard Adams⁵, Magda Meissner¹, Sophie Shaw²

1. Cardiff University
2. All Wales Medical Genomics Lab (AWMGL)
3. Velindre Cancer Centre
4. Centre for Trials Research
5. University of Birmingham

The DNA sensor IFI16 functions in the replication stress response in cancer cells

Jahnvi Rajan¹, Caryl Jones¹, Christopher Staples¹

1. Bangor University

Ruthenium Polypyridyl Complexes in the Exploration of Mismatch DNA

Natalia Kolozsvari¹, Christopher E. Elgar¹, Paul R. Tiley¹, Gareth J. Jenkins², Martin R. Gill¹

1. Department of Chemistry, Swansea University, UK
2. Swansea University Medical School, Swansea University, UK

NFIA::CBFA2T3 expression promotes growth and survival of human erythroid cells

Ellie McCracken¹, Siân Rizzo¹, Owen Hughes¹, Maryam Alanazi^{1,2}, Abdulsalam M Alruwaili^{1,3}, Maryam Halawi^{1,4}, Raymond Toghill⁵, Amanda Gilkes¹, Zulfa Yoosuf Aly¹, Brian L Calver¹, Steve Knapper^{1,6}, Richard Darley¹, Alex Tonks¹

1. Department of Haematology, Division of Cancer & Genetics, School of Medicine, Cardiff University
2. Shaqra University, College of Applied Medical Science, Shaqra, Saudi Arabia
3. Shaqra University, College of Pharmacy, Jazan, Saudi Arabia
4. Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan, Saudi Arabia
5. Department of Haematology, University Hospital of Wales, Cardiff and Vale University Health Board
6. Cardiff University, Cardiff Experimental and Cancer Medicine Centre, School of Medicine, Cardiff, United Kingdom

Exploring Telomeric Chromatin Interactions throughout Replicative Crisis in Colorectal Cancer Cells

Julie E. Thornton¹, Emmon Coral¹, Duncan M. Baird¹, Kate Liddiard¹

1. Division of Cancer and Genetics, School of Medicine, Cardiff University

Toward Clinically Deployable Diffusion MRI Virtual Biopsy

Yang Yang^{1,2}, Leandro Beltrachini^{1,2} etc.

1. School of Physics and Astronomy, Cardiff University, Cardiff, United Kingdom
2. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom

Telomere Crisis Generates Highly Complex Rearrangements and Tumour-Specific Neoantigens

Vanda Miklos¹, Kez Cleal¹, Barbara Szomolay², Sara Seifan¹, Duncan Baird¹

1. Division of Cancer and Genetics, School of Medicine, Cardiff University
2. Division of Infection and Immunity, School of Medicine, Cardiff University

The function of protein lactylation in cisplatin-resistant ovarian cancer cells via targeting of monocarboxylate transporters (MCTs)

Fariba Mirani¹, Fadi Alanazi¹, Tomos Walker¹, Christopher J. Staples¹, Jonathan L. Blank¹

1. North West Cancer Research Institute, North Wales Medical School, Bangor University, LL57 2UW, UK

Development of Precision Virotherapies for Diffuse Midline Gliomas

Mariana Varela Pereira¹, Emily A. Bates¹, Florian Siebzehrubl², Chris Jones³, William Gray⁴ and Alan L. Parker¹

1. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff
2. European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff
3. The Glioma Group, Institute of Cancer Research, London
4. Neuroscience and Mental Health Innovation Institute, School of Medicine, Cardiff University, Cardiff

Immuno-oncology

Development of a novel combination immunotherapy for the treatment of $\alpha\beta$ 6-positive solid tumours

Rebecca J Bayliss^{1,3}, Elise Moses¹, Ben de Wet², Alan L Parker^{1,3}

1. Division of Cancer and Genetics, School of Medicine, Cardiff University.
2. Immunocore Ltd, Milton Park, Abingdon, Oxfordshire.
3. Wales Applied Virology Unit, School of Medicine, Cardiff University.

β 2M-loss in cancer exposes potent HLA-independent T-cell receptors and reveals a gateway to universal cancer targeting.

Li Rong Tan¹, Mateusz Legut¹, Théo Morin¹, Marine E. Caillaud¹, Cristina Rius¹, Aaron Wall¹, Marco Donia², Inge Marie Svane², John Phillips³, Barbara Szomolay^{1,4}, Garry Dolton¹ and Andrew K. Sewell¹.

1. Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, UK.
2. Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark,
3. Division of Haematology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States of America.
4. Systems Immunology Research Institute, Cardiff University, Cardiff, Wales, UK.

[Winner: Scientific excellence award] Optimising anti-PI3K δ and anti-LAG-3 immunotherapy dosing regimens for triple negative breast cancer improves outcome by removing treatment-related adverse events

Sarah N Lauder¹, Ana Pires¹, Michelle Somerville¹, Lorenzo Capitani¹, Kathryn Smart¹, James Geary¹, Emily M Mills¹, Bart Vanhaesebroeck², Andrew Godkin¹, Awen Gallimore¹.

1. Division of Infection and Immunity, Cardiff University School of Medicine, SIURI, Cardiff, CF14 4XN, UK
2. UCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street, London WC1E 6BT, UK

PROTACs enhance the presentation of MHC class I peptides through increased degradation of targeted proteins: A method for making cancers more visible to antigen-specific T cells

Emily Mills¹, Sarah Lauder¹, Kathryn Smart¹, Saul Michue-Seijas², Hannah Cole², James Geary¹, Andrew Godkin¹, Heulyn Jones², Awen Gallimore¹

1. Division of Infection and Immunity, Cardiff University
2. Medicines Discovery institute, Cardiff University

A Patient-Derived Organoid Platform for Systematic Identification of Colorectal Cancer-Specific Epitopes

Chloe Harris¹, Stefan Milutinovic¹, Stephanie Burnell¹, Lorenzo Capitani¹, Carina Owen¹, Kasope Wolffs^{1,2}, Andrew Godkin^{1,3}, Awen Gallimore¹

1. Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
2. Wales Cancer Bank, UHW Main Building, Heath Park, Cardiff, CF14 4XN, UK.
3. Department of Gastroenterology and Hepatology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK. 4Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

Immune Activation Reshapes Tumour Vasculature Potentiating Successful Anti-Tumour Responses to Anti-Angiogenic Co-Therapy

Stefan Milutinovic¹, Sarah Lauder¹, Kathryn Smart¹, Marc Hillgaertner¹, Michelle Somerville¹, Andrew Godkin¹ and Awen Gallimore¹

1. Division of Infection and Immunity, Systems Immunity University Research Institute, Cardiff Cancer Research Partnership, School of Medicine, Heath Park, Cardiff, CF119HP.

Oncolytic Adenovirus 5 Mediated Prodrug Conversion Therapy for use in Glioblastoma

Wallace Rebecca¹, Bates A Emily¹, Parker L Alan¹

1. Cardiff University, School of Medicine

Evaluating microglia phenotypes and patient-specific glioblastoma-microglia interactions using a dynamic 3D iPSC-derived brain organoid model

Julia Spagnolello¹

1. Cardiff University

In vivo reprogramming of extracellular vesicles: developing a platform technology to enhance cancer vaccines

Aimee P. Lucignoli¹, Kevin D. Thiessen², Kate F. Milward¹, Jason P. Webber³, Alan L. Parker^{1,4}, Rebecca J. Richardson², Carly M. Bliss^{1,4,5}

1. Division of Cancer & Genetics, School of Medicine, Cardiff University
2. School of Biochemistry and Biomedical Science, University of Bristol
3. Institute of Life Science, Swansea University Medical School, Swansea University
4. Wales Applied Virology Unit, Cardiff University
5. Systems Immunity University Research Institute, Cardiff University

Development of Ad5NULL-DogTag: A native tropism-ablated, flexible platform for precision adenoviral therapy vector targeting

Emma A. Swift¹, Alan L. Parker^{1,2,3}

1. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK
2. Systems Immunity University Research Institute, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK
3. Wales Applied Virology Unit (WAVU), Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN

Investigating adenovirus 49 as a potential oncolytic virus

Rosie M. Mundy¹, Jasmine Caldwell¹, Charlotte Lovatt¹, Yuan Chen², Antonio Di Maio², Yan Liu², David A. Matthews³, Alan L. Parker^{1,4}

1. Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN
2. Department of Metabolism, Digestion and Reproduction, Glycosciences Laboratory, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 0NN
3. Department of Cellular and Molecular Medicine, School of Medical Sciences University Walk, University of Bristol, Bristol, BS8 1TD
4. Systems Immunity University Research Institute, Cardiff University School of Medicine, Cardiff, CF14 4XN

Manipulating T-cell immune responses to improve anti-Glioblastoma immunity

Mathew Clement^{1,2}, Michelle Somerville¹, Sarah Lauder¹, Stefan Milutinović¹, Florian Siebzehrnubi³ & Awen Gallimore^{1,2}

1. Division of Infection & Immunity, School of Medicine, Cardiff University.
2. Systems Immunity Research Institute, School of Medicine, Cardiff University.
3. European Cancer Stem Cell Institute, Cardiff University.

Radiotherapy

Design of ruthenium(II) polypyridyl complexes as new radiosensitizers

Natalia Kolozsvari¹, Sujani Imaduwa Wickrama Acharige¹, James Cronin², Christopher Staples³, Martin R. Gill¹

1. Department of Chemistry, Swansea University
2. Department of Biomedical Sciences, Swansea University
3. School of Medical Sciences, Bangor University

UK radiotherapy practice for Oligodendroglioma -data from the APPROACH trial (ISRCTN:1339049) radiotherapy quality assurance (RTQA) programme

Jennifer Golten^{1,2}, Anna Bruce^{3,4}, Daniel Egleston^{3,4}, Elizabeth Miles^{3,5}, James Powell^{1,2}, Louise Murray^{6,7}

1. Velindre University NHS Trust
2. Cardiff University,
3. National Radiotherapy trial Quality Assurance (RTTQA) group,
4. Clatterbridge Cancer Centre,
5. Mount Vernon Cancer Centre,
6. St James' University Hospital
7. Leeds Institute of Medical Research, University of Leeds

Re-audit of outcomes and toxicity following stereotactic radiosurgery for brain metastases at Velindre Cancer Centre, comparing patients with brain metastases from common versus uncommon primary tumour sites.

Ali Hussnain¹, Nicholas Gomez¹, Sara Walters¹, Jason Griffiths¹, Jillian MacLean¹, Najmus Sahar Iqbal¹ and James Powell^{1,2}

1. Oncology Department, Velindre Cancer Centre, Cardiff
2. School of Medicine, Cardiff University

Radiomics for Predicting Treatment Response and Prognosis in Rectal Cancer: A Systematic Review of Multimodal Imaging, Standardization, and Delta-Radiomics

Yiwen Dong¹, Emiliano Spezi², Richard Adams³

1. School of Engineering, Cardiff University
2. School of Engineering, Cardiff University
3. Cardiff University School of Medicine and Velindre University NHS Trust

Hippocampal Dosimetry and Neurocognitive Function in Patients undergoing Stereotactic Radiosurgery

Najmus Sahar Iqbal^{1,2}, Michelle Smalley³, Tara Daisley-Devoy⁴, Maeve Williams⁵, John N Staffurth^{1,2}, Jillian Maclean¹, James R Powell^{1,2}

1. Velindre University NHS Trust, Clinical Oncology, Cardiff, United Kingdom
2. Cardiff University, School of Medicine, Cardiff, United Kingdom
3. Cwm Taf University Health Board, Clinical Psychology, Cardiff, United Kingdom
4. University of Bath, Clinical Psychology, Bath, United Kingdom
5. Velindre University NHS Trust, Medical Physics, Cardiff, United Kingdom

[Winner: Clinical research award] Hippocampal dosimetry and implication for treatment planning in patients undergoing stereotactic radiosurgery for limited brain metastases

Najmus Sahar Iqbal^{1,2}, Maeve Williams², Matthew Williams², Ceri Doherty², Andrew Bryant², Michael Chu², Jillian Maclean², Anthony Millin², Nachi Palaniappan², John Staffurth^{1,2} & James Powell^{1,2}

1. School of Medicine, Cardiff University, Cardiff.
2. Velindre University NHS Trust, Cardiff.

Phase 1b/II trial of pembrolizumab plus standard radiotherapy with chemotherapy in Squamous Cell Carcinoma of anus (CORINTH): Cohorts safety data

Lisette Nixon¹, Margherita Carucci¹, Angela Casbard¹, Lawrence Raisanen¹, Catharine Porter¹, Philip J Markham¹, John Lindley¹, Marianne G. Guren², Vicky Goh³, Thomas Rackley⁴, Samuel Bosompen⁶, Natalie L Abbott⁴, Morny Drury⁷, Marcia Hall⁵, Mark Harrison⁵, Richard Adams¹

1. Centre for Trials Research, Cardiff University, Cardiff, UK
2. Oslo University Hospital, Oslo, Norway
3. School of Biomedical Engineering & Imaging Sciences, King's College London, London; UK
4. RTTQA, Cardiff & London, UK
5. Mount Vernon Cancer Centre, Northwood, UK
6. Frimley Health NHS Foundation Hospital, Slough, UK
7. Consumer Representative

Promoting recruitment and ensuring quality of treatment delivery in the UK's 1st proton radiotherapy trial in oesophageal cancer

Shannon Rowlands¹, Sarah Gwynne^{1,2}, Owen Nicholas¹, Ganesh Radhakrishna³, Geraint Lewis^{2,4}, Fiona Williams⁴, Jonathan Helbrow^{2,5}

1. South West Wales Cancer Centre
2. NIHR RTTQA group
3. The Christie NHS Foundation Trust
4. Velindre Cancer Centre
5. Gloucestershire Hospitals NHS Foundation Trust

Cancer clinical trials

Striving for Excellence: A CCRP Online Survey into Consultant Investigator Experience of the Velindre Cancer Centre Clinical Trial Pipeline

Richard Bennett¹, Ricky Frazer², Emma Barker³

1. Oncology, Velindre Cancer Centre
2. Oncology, Velindre University NHS Trust
3. Clinical Trials, Cardiff Cancer Research Partnership

From CKD to Surgical Oncology: Leveraging Digital Health for Kidney Cancer Prehabilitation

Prem Sharma¹, Praboda Rajapaksha^{1,3*}, Edore Akpokodje^{1*}, Federico Villagra Povina², Peter Herbert³, Meryl James³, Nicola Thomas³, Subhamay Ghosh³

1. Department of Computer Science, Aberystwyth University, Llandinam Building, Penglais, Aberystwyth
2. Department of Life Sciences, Aberystwyth University, Carwyn James Building, Penglais, Aberystwyth
3. Hywel Dda University Health Board, NHS Wales, Carmarthen, UK

* Equal contributors

Corresponding author - Edore Akpokodje (eta@aber.ac.uk)

PATHOS-10: CRUK-Funded Extended Long-Term Follow-Up of Functional and Survivorship Outcomes After Risk-Adapted Treatment for HPV-Positive Oropharyngeal Cancer

Christie Heiberg¹, Joanna Canham¹, Christopher Hurt², Ceri Frayne¹, Sean Johnson¹, Lisette Nixon¹, Mererid Evans³, Terry M Jones⁴

1. Centre For Trials Research, Cardiff University
2. Southampton Clinical Trials Unit, University of Southampton
3. Division of Cancer and Genetics, Cardiff University and Dept. of Clinical Oncology, Velindre University NHS Trust
4. Liverpool Head and Neck Centre, Faculty of Health and Life Science, University of Liverpool

Patients' and healthcare professionals' experiences of the CHRONOS Trial exploring NOvel surgery in prostate cancer

Dr Daniella Holland-Hart¹, Dr Deepika Reddy³, Dr Thiagarajah Sasikaran², Ms Puja Jadav², Mr Taimur Shah³, Professor Hashim Ahmed³, Dr Mirella Longo¹

1. Division of Population Medicine, Cardiff University.
2. Imperial Clinical Trials Unit, Imperial College London.
3. Imperial College Healthcare NHS Trust.

Palliative and supportive oncology

Factors Affecting Treatment Resilience in Patients with Oesophago-Gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review.

Dr Kiran Datta¹, Professor Anthony Byrne², Dr Daniella Holland-Hart^{3*}

1. Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom.
2. Velindre NHS Trust, Wales, United Kingdom.
3. Marie Curie Research Centre, Division of Population Medicine, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom

Antithrombotic therapy management in patients with cancer approaching end-of-life: a mixed-method integration using joint display analysis

Elin Baddeley¹, Lisanne van't Walderveen², Helle Enggaard³, Mette Søggaard⁴, Denise Abbel², Suzanne Cannegieter⁵, Michelle Edwards¹, Carme Font⁶, Jamilla Goedegebuur⁵, F.A. Klok², Kate J. Lifford¹, Isabelle Mahé⁷, Simon P. Mooijaart⁸, Simon Noble¹, Mark Pearson⁹, Kathy Seddon¹, Stephanie Sivell¹, Sebastian Szmit¹⁰, Stella Trompet⁸, Anette Arbjerg Højten⁴

1. Division of Population Medicine, School of Medicine, Cardiff University, Cardiff - UK
2. Department of Medicine, Leiden University Medical Center, Leiden - The Netherlands
3. Clinical Nursing Research Unit & Clinical Cancer Research Center, Aalborg University Hospital, Aalborg - Denmark
4. Danish Center for Health Services Research, Aalborg University and Aalborg University Hospital, Aalborg - Denmark;
5. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden - The Netherlands
6. Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona - Spain;
7. Internal Medicine Department, Paris Cité Université, Paris - France;
8. Department of Internal Medicine, Leiden University Medical Center, Leiden - The Netherlands
9. Wolfson Palliative Care Research Centre, Hull York Medical School, Hull - UK;
10. Department of Cardio-Oncology, Centre of Postgraduate Medical Education, Warsaw - Poland

The needs of people living with glioma; a secondary analysis of qualitative data to standardise outcomes used in routine care.

Noreen Hopewell-Kelly¹, Vimeeka Raj Devarajan¹, Helen Bulbeck², Rhian Burke³, Anthony Byrne^{3,4}, Andrew Carson-Stevens¹, Gwawr Evans⁵, Cressida Lorimer⁶, James Powell³, Sarah Puntoni⁷, Alasdair G Rooney⁸, Kathy Seddon¹, Colin Watts⁹, Stephanie Sivell¹, Ameeta Retzer¹⁰

1. Division of population medicine, Cardiff University
2. brainstrust - the brain cancer people
3. Velindre Cancer Centre, Velindre University NHS Trust
4. Marie Curie Hospice, Cardiff and the Vale
5. Velindre University NHS Trust
6. Oncology Department, University Hospitals Sussex NHS Foundation Trust
7. NHS Wales Performance and Improvement
8. Centre for Clinical Brain Sciences, The University of Edinburgh
9. Department of Cancer and Genomic Sciences, University of Birmingham
10. Health Services Management Centre, University of Birmingham

An updated systematic review and qualitative synthesis of the lived experience of people living with glioma (Core Outcomes to Measure clinical needs for people with primary Brain Tumours: COMBaT Study).

Vimeeka Raj Devarajan¹, Silvia Goss¹, Noreen Hopewell-Kelly¹, Helen Bulbeck², Rhian Burke³, Anthony Byrne^{3,4}, Andrew Carson-Stevens⁵, Gwawr Evans⁶, Cressida Lorimer⁷, James Powell³, Sarah Puntoni⁸, Alasdair G Rooney⁹, Kathy Seddon¹, Colin Watts¹⁰, Ameeta Retzer¹¹, Stephanie Sivell¹

1. Marie Curie Research Centre, Division of population medicine, Cardiff University
2. Services and policy, brainstrust - the brain cancer people
3. Velindre Cancer Centre, Velindre University NHS Trust
4. Marie Curie Hospice, Cardiff and the Vale
5. Division of Population Medicine, Cardiff University
6. Value-based healthcare, Velindre University NHS Trust
7. Oncology Department, University Hospitals Sussex NHS Foundation Trust
8. NHS Wales Performance and Improvement
9. Centre for Clinical Brain Sciences, The University of Edinburgh
10. Department of Cancer and Genomic Sciences, University of Birmingham
11. Health Services Management Centre, University of Birmingham

Gamifying Early Oncology Education: A Hospice-Themed Escape Room for Second-Year Medical Students in Palliative Care Foundations

Alice Crabtree¹, James Davies¹, Kate Hilson¹, Sarju Patel¹, Karen Reed¹, Hannah West¹, Siwan Seaman¹

1. Velindre Cancer Centre, Cardiff and Vale UHB, Cardiff University School of Medicine, Marie Curie Hospice, Cardiff and the Vale.

Population health-based cancer prevention, detection, primary care and health service research

Cancer prehabilitation can be inclusive for individuals from diverse and low-income communities by prioritising cultural relevance and involving friends and family.

Dr. Sarah Fry¹; Dr. Nichola Gale¹; Professor Emerita Jane Hopkinson¹; Dr. Alexandra Mitchell¹; Manasi Patil¹; Professor Shea Palmer¹

1. School of Healthcare Sciences, Cardiff University, on behalf of the NIHR I-Prehab Project research team

Cancer incidence in Wales: historical trends and projections to 2035 using novel methods

Rosemary Walmsley¹, Leon May¹, Serenay Ozalp¹, Jonathan Rees¹, Ffion Thomas¹, Rebecca Thomas¹, Stephanie Smits¹, Dyfed Wyn Huws^{1,2}, Louisa Nolan¹, Llion Davies¹

1. Research, Data, and Digital Directorate, Public Health Wales
2. Population Data Science, Swansea University

Exploring the Impact of Diagnostic Setting on Survival for Individuals Diagnosed with Cancer and Cardiovascular Disease in Wales.

Caitlin Partridge¹, James Rafferty¹, Mark Davies², Keith R Abrams³, Rhiannon K Owen¹

1. Population Data Science, Swansea University
2. Division of Cancer and Genetics, Cardiff University
3. Department of Statistics, University of Warwick

Integrated Urinary Omics suggests Immune Dysregulation in Breast Cancer

Nur Aimi Aliah Zainurin¹, Manfred Beckmann¹, Helen Phillips¹, Russell Morphew¹, Matthew Hegarty¹, Robert Andrews³, Alex Gibbs³, Dimitra Ivanova¹, Tim Gate⁴, Helen Tench⁵, Mandana Pennick², Luis A J Mur¹

1. Department of Life Sciences, Aberystwyth University, Aberystwyth, SY23 3DA, United Kingdom
2. Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Bodelwyddan, LL18 5UJ, United Kingdom
3. Cardiff University, Sir Geraint Evans Building, Academic Avenue, Heath Park, CF14 4XN, United Kingdom
4. Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, LL13 7TD, United Kingdom
5. Bronglais General Hospital, Hywel Dda University Health Board, SY23 1ER, United Kingdom

The All-Wales Colorectal Peritoneal Metastases Service: stakeholder feedback for a newly developed CRS and HIPEC centre

Sivakumar Jayakumar¹, Jody Parker¹, Caroline Trezise¹, Leigh Davies¹

1. Department of Colorectal Surgery, Cardiff and Vale University Health Board

Peer-led WhatsApp messaging is acceptable for sharing prostate cancer risk information among Black men: Pilot study results.

Dr Sarah Fry¹; Dr Kai Wakeham¹; Dr Shancang Li²; Dr George Theodorakopoulos²; Dr Nicholas Courtier¹; Dr Harriet Quinn-Scoggins³

1. School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff University
2. School of Computer Science and informatics, College of Physical Sciences and Engineering, Cardiff University
3. PRIME Centre Wales, Division of Population Medicine, School of Medicine, College of Biomedical and Life Sciences, Cardiff University

Leveraging Lymph Node Micro-Anatomy to Improve Detection of Isolated Tumour Cells in Whole Slide Pathology Images

Burhanuddin Anis¹, Dr. Adam Vincent Jones², Dr. Miranda Pring³, Prof. Paul Rosin⁴

1. School of Dentistry, Cardiff University
2. Department of Pathology, University Hospital Wales
3. Head and Neck, Severn Pathology, University of Bristol
4. School of Computer Science and Mathematics, Cardiff University

Developing a Community Pharmacy Service to Facilitate Early Diagnosis of Bowel Cancer: Survey of Pharmacy Staff

Christian Von Wagner¹, Savita Shanbhag², Harriet Quinn-Scoggins³, Caroline Clarke¹, Jack Hogton³, Sophia Harmer¹, Evelyn Brunson¹

1. University College London
2. Hywel Dda UHB
3. Prifysgol Caerdydd/Cardiff University

[Winner: Patient and public involvement award] Awareness, discussions around and use of prostate specific antigen (PSA) testing among men living in the United Kingdom (UK): a national online survey

Stefanie Bonfield¹, Harriet Quinn-Scoggins¹, Jo Waller¹, Laura Marlow¹

1. Centre for Cancer Screening Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London

Reimagining Gynaecological Cancer Detection: Patient Perspectives on Liquid Biopsy Blood Testing

Nerissa E. Thomas^{1,2}, Ashra Khanom¹, Alix Bukkfalvi-Cadotte¹, Charles D. Brilliant², Laura E. Thomas¹, Dean A. Harris^{1,2}

1. Swansea University Medical School, Swansea University
2. Cansense

Establishing a Population-Scale Oncology Cohort via the SAIL Databank to Support Cancer Research in Wales.

Laura Baker¹, Arron Lacey¹, Ashley Akbari¹, Sunil Dolwani²

1. Population Data Science, Medical School, Swansea University, Wales.
2. Gastroenterology, Cardiff and Vale University Health Board, Wales.

Understanding equity in cancer prehabilitation services in Wales: A medical record review.

Shea Palmer¹, Alexandra Mitchell¹, Akhilesh Ramachandran¹, Nichola Gale¹, Sian Lewis², Manasi Patil¹, Nicholas Courtier¹, Jane Hopkinson¹

1. School of Healthcare Sciences, Cardiff University
2. Aneurin Bevan University Health Board

Abstracts

Precision and mechanistic oncology

Calpain as a novel therapeutic target in breast cancer

Danielle Harper¹, Ivan Shapovalov¹, Jung Yeon Min¹, Samantha Cockburn¹, Anya Aaron¹, Brian J. Laight¹, Yan Gao¹, and Peter A. Greer¹

1. Division of Cancer Biology and Genetics, Sinclair Cancer Research Institute, Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario

The cells of origin of the chemotherapy curable malignancies are highly sensitive to cytotoxic chemotherapy and the induction of apoptosis.

Emily Proudman¹, Philip Savage¹

1. Cardiff University

Inhibition of cFLIP attenuates the amplification of Cancer Stem Cell (CSC)-like activity after chemotherapy.

Timothy Robinson¹, Gillian Seaton², Rhiannon French², Daniel Turnham², Valerie Meniel², Richard Clarkson²

1. Bristol Medical School (PHS), University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN.
2. European Cancer Stem Cell Research Institute, Cardiff University School of Biosciences, Hadyn Ellis Building, Maindy Road, Cardiff CF24 4HQ.

Oxidative DNA damage repair and chromosome breakage (micronuclei) in oesophageal disease progression: exploring the link between blood and tissue mutation levels

Kate Hurlow¹, Hamsa Naser¹, Kathryn Munn¹, Kate Chapman¹, Lisa Williams², Will Beasley², Gareth Jenkins¹

1. In Vitro Toxicology Group, Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK
2. Department of Gastroenterology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK

A Mathematical framework to predict Adaptive Therapy success through early response dynamics.

Liam Ryall-Friend¹, Mark Davies², Noemi Picco¹

1. Department of Mathematics, Swansea University.
2. Department of Cancer and Genetics, Cardiff University.

HSP90A as a Novel Candidate Therapeutic Target in the regulation of EGFR following the loss of Kidins220 using RNA sequencing analysis in pancreatic cancer

Deepa Shankla¹, Qingping Dou², Wen G. Jiang¹ and Lin Ye¹

1. Cardiff China Medical Research Collaborative, Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK.
2. Barbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, MI 48201, USA

The use of multiomics to better inform drug development for advanced breast cancer beyond current techniques: A Scoping Review.

Emily Berry¹, Professor Emiliano Spezi¹, Professor Richard Adams^{2,3}

1. School of Engineering, Cardiff University
2. School of Medicine, Cardiff University
3. Velindre Cancer Centre

Do Cutibacterium acnes extracellular vesicles mediate the inflammatory host response in prostate cancer?

Luka Brajdic¹, Helen B. Pearson², Helen L. Brown¹

1. School of Biosciences, Cardiff University
2. European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University

Pharmacological Targeting of Bcl3 in Models of Breast and Colorectal Cancer

Hannah Smith¹, Will Yang¹, Adam Higgins¹, Gillian Seaton¹, Andrew Westwell², Andrea Brancale³ and Richard Clarkson¹

1. European Cancer Stem Cell Research Institute, Cardiff University School of Biosciences, Haydn Ellis Building, Maindy Road, Cardiff, Wales, UK. CF24 4HQ.
2. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, U.K.
3. Department of Organic Chemistry, University of Chemistry and Technology, 16628 Prague, Czech Republic.

Discovery of Novel Anticancer Bcl3 Inhibitors

Tia Z. Elstow¹, Dusan Ruzic¹, Andrea Brancale², Richard W. E. Clarkson³, Andrew D. Westwell¹

1. School of Pharmacy and Pharmaceutical Sciences, Cardiff University
2. Department of Organic Chemistry, University of Chemistry and Technology, Prague
3. European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University

Design and Synthesis of Small-Molecule Inhibitors Targeting MRE11 Nuclease Activity

Eleanor Ashcroft^{1,2,4}, Edgar Hartsuiker¹, Mark Young², Salvatore Ferla³, Marcella Bassetto⁴

1. North Wales Medical School, Bangor University
2. School of Biosciences, Cardiff University
3. Medical School, Pharmacy, Swansea University
4. School of Pharmacy and Pharmaceutical Sciences, Cardiff University

Statistical Description of Prostate Microstructure for Cancer Grading

Morgan Williams¹, Leandro Beltrachini¹

1. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University

Stem-Like Cancer-Initiating Cells and Cell-Cell Signalling Drive PanIN Progression in Pancreatic Cancer

Salvador-Barbero B^{#1}, Reed E¹, Ruiz-Palacios D², Pedraza S², Ibanez A², Castano JP², Hogan C^{#1}

1. European Cancer Stem Cell Institute, Cardiff University
2. Instituto Maimonides de Investigacion Biomedica de Cordoba

Engineering Human Adenovirus Type 10 for Tumour-Selective Virotherapy

Mahulena Marušková¹, Emily A. Bates¹, Rebecca Wallace¹, Rebecca J. Bayliss^{1,2}, Alan L. Parker^{1,2}

1. Division of Cancer and Genetics, School of Medicine, Cardiff University
2. Wales Applied Virology Unit, School of Medicine, Cardiff University

Knowing the unknown: Real world outcome of Molecular Profiling (MP) in Carcinoma of Unknown Primary (CUP) patients referred to regional (South East Wales SEW) CUP service

Sonali Dasgupta¹, Maleeha Anwar¹, George Joseph², Veena Joseph², Anurag Joshi³, Meleri Morgan³, Alice Richards³, Sian Morgan⁴

1. Oncology, Velindre University NHS Trust
2. Radiology, Velindre University NHS Trust
3. Pathology, Cardiff and Vale University Health Board
4. Genomics, All Wales Medical Genomics Service (AWMGS)

Immuno-oncology

A pre-clinical adenoviral vectored cancer immunotherapy designed to harness antiviral immunity against cancer cells

Kate Milward¹, Aimee Lucignoli¹, Katie Topley², Elise Moses¹, Garry Dolton², Lucy C Jones^{2,3}, Andrew Sewell^{2,4}, Carly M Bliss^{1,4,5}, Alan L. Parker^{1,4,5}

1. Division of Cancer & Genetics, Cardiff University
2. Division of Infection & Immunity, Cardiff University
3. Cwm Taf Morgannwg University Health Board
4. Systems Immunity University Research Institute (SIURI), Cardiff University
5. Wales Applied Virology Unit (WAVU), Cardiff University

Targeting glioblastoma with precision adenoviral therapies

E. A. Bates¹, R. J. Bayliss¹, M. Maruskova¹, A. L. Parker¹

1. Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.

3MERLIN: Myasthenia, Myositis, Myocarditis syndrome (3M) Epidemiology, Registry founding, and Laboratory Insights

Ben Schroeder^{1,2}, Arron Lacey³, Laura Baker³, Samra Turajilic^{4,5}, Max Emmerich^{4,5}, Simon Jones^{6,7}, Anna Olsson-Brown^{8,9}, Heather Shaw^{10,11}, Ricky Frazer¹², Arjun Ghosh^{13,14}, Kate Young⁴, Hester Franks^{15,16}, Clare Barlow¹⁷, Helen Winter¹⁸, Stephen Keddie¹⁹, Maria I Leite^{20,21}, Sam Clark²², Neil Robertson^{1,2}, Aisling Carr^{23,24}, Mark Willis^{1,2}

1. Department of Neurology, University Hospital of Wales, Cardiff, Wales, UK.
2. Department of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, Wales, UK.
3. School of Medicine, Swansea University, Swansea, Wales, UK
4. Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK.
5. Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
6. Systems Immunity Research Institute, Cardiff University, Cardiff, UK
7. Hodge Centre for Translational Neuroscience, Cardiff University, Cardiff, UK
8. Sussex Cancer Centre, University Hospitals Sussex, Sussex, UK
9. Dept of Clinical and Molecular Pharmacology, University of Liverpool, Liverpool, UK
10. Mount Vernon Cancer Centre, East and North Hertfordshire NHS Foundation Trust, UK
11. Department of Oncology, University College London Hospitals, London, UK
12. Velindre Cancer Centre, Cardiff, UK
13. Barts Heart Centre, Barts Health NHS Trust, London, UK
14. Cardio-oncology, University College London Hospitals, London, UK
15. Centre for Cancer Sciences, Translational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
16. Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
17. Somerset Foundation Trust, Musgrove Park Hospital, Parkfield Drive, Taunton, Somerset TA1 5DA, UK
18. The Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8ED, UK
19. Department of Neurology, The Royal London Hospital, London, England, UK.
20. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, England, UK.
21. Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, England, UK.
22. Critical Care, University College London Hospitals, London, UK
23. Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, England, UK.
24. Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, England, UK

ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem)

Hayley Timmins¹, Ashley Osborne², Rebecca Cox², Joanna Canham¹, Muhammad Riaz¹, Huda Mohamed¹, Harpreet Wasan³, Pippa Corrie⁴, Roopinder Gillmore⁵, Mabel Teng⁶, Olusola Faluyi⁷, Arvind Arora⁸, Seema Arif⁹, Paul Miller¹⁰, Richard A Hubner², John Bridgewater¹¹, Richard Adams^{1,9}, Juan W Valle^{12,2,13}, Mairéad G McNamara^{12,2}

1. Cardiff University
2. The Christie NHS Foundation Trust
3. Imperial College Healthcare NHS Trust
4. Cambridge University Hospitals NHS Foundation Trust
5. Royal Free London NHS Foundation Trust
6. University Hospitals Birmingham NHS Foundation Trust
7. Clatterbridge Cancer Centre NHS Foundation Trust
8. Nottingham University Hospitals NHS Trust
9. Velindre University NHS Trust
10. Oxford University Hospitals NHS Foundation Trust
11. University College London Hospitals NHS Foundation Trust
12. University of Manchester
13. The Cholangiocarcinoma Foundation

Immune-competent iPSC-brain organoids: the dialogue between myeloid and lymphoid cells within Glioblastoma microenvironment

Giulia A Ionescu¹, Cátia Neto¹

1. Cardiff University, School of Pharmacy and Pharmaceutical Sciences

Localised delivery of chemoattractants and immune checkpoint inhibitors using a precision virotherapy in pancreatic cancer

Charley Lovatt-Travers¹, Luned M. Badger¹, Catherine Hogan^{1,2}, Alan L Parker¹

1. Division of Cancer and Genetics, Cardiff University School of Medicine
2. European Cancer Stem Cell Research Institute, Cardiff University School of Biosciences

Radiotherapy

Green-dMRIPrep: diffusion MRI preprocessing pipeline with integrated QC, energy tracking, and carbon emissions auditing

Muhammad Usman Akbar^{1,2}, Maëlliss Jallais^{1,2}, Marco Palombo^{1,2}

1. Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom
2. School of Computer Science and Informatics, Cardiff University, Cardiff, United Kingdom

Radiotherapy QA of hippocampus and hypothalamus contouring for the APPROACH (Analysis of Proton vs Photon Radiotherapy in Oligodendroglioma and Assessments of Cognitive Health) trial (ISRCTN:1339049)

Jennifer Golten^{1,2}, Emiliano Spezi^{1,3}, Anna Bruce^{4,5}, Daniel Egleston^{4,5}, Elizabeth Miles^{4,6}, James Powell^{1,2}, Louise Murray^{7,8}

1. Velindre University NHS Trust
2. Cardiff University, School of Medicine
3. Cardiff University, School of Engineering
4. National Radiotherapy Trials Quality Assurance (RTTQA) group
5. Clatterbridge Cancer Centre
6. Mount Vernon Cancer Centre
7. St James's University Hospital
8. Leeds Institute of Medical Research, University of Leeds

Combining Radiotherapy with ART1 Inhibition Remodels the Tumour Immune Landscape in an Immune-Cold Model of Head and Neck Cancer

Jessica Oliver¹, Victor Gray¹, Ricardo Sainz¹, Linda Li¹, Kevin Harrington¹, Erik Wennerberg¹

1. The Institute of Cancer Research, London, United Kingdom

Developing and optimising Magnetic resonance imaging and Spectroscopy for use in Radiotherapy (MRinRT) pathways: Investigating avenues to improve outcomes for patients and the assessment of treatment response

Clair Brunner¹, Adam Cooper¹, Nicholas Gomez¹, Stephen Bawden¹, Samantha Telfer¹, Owen Bodger², Kieran Foley³, Jonathan Phillips^{1,2}, Owen Nicholas^{1,2}

1. Swansea Bay University Health Board
2. Swansea University
3. Cwm Taf Morgannwg University Health Board

Systematic review of the benefit of MRI for radiotherapy planning for gastro-oesophageal cancers

Clair Brunner¹, Lizzy Evans¹, Richard Hugtenburg^{1,2}, Owen Nicholas^{1,2}, Sarah Gwynne^{1,2}

1. Swansea Bay University Health Board
2. Swansea University

Palliative and supportive oncology

Specialist Neuro-oncology community therapy services: addressing inequalities and gaps in service provision.

Cathryn Lewis¹, Carmen Reed¹, Sarah Cordeaux¹, Rhian Burke¹, Charlotte John¹, Rebekah Trapnell¹, Deborah Mullan¹, Nichola Gale², Helen Williams³, Thomas Howson³

1. Velindre Cancer Service
2. Cardiff University
3. Bevan Commission

Population health-based cancer prevention, detection, primary care and health service research

Developing an efficient and effective structural variant calling pipeline for a clinical cancer profiling context

Ashley J. Pridgeon¹, Erik Waskiewicz¹, Sophie Shaw¹, Duncan Baird², Kez Cleal²

1. All Wales Medical Genomics Service, Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, UK
2. Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, UK

Addressing Variation in Symptomatic FIT Use Across Wales: Insights from a National Dashboard

Benjamin Hughes¹, Habib Khalil¹, Bethan Watson¹, Stevie Davies², Alun Matthews², Ian Leigh², Daniel Cullen¹, Raul Garcia¹, Jeff Turner²

1. Digital Health and Care Wales, NHS Wales
2. NHS Wales Performance and Improvement

Enhancing Personalised Management of Active Surveillance in Prostate Cancer: Developing and Applying Explainable Artificial Intelligence (xAI) Tools to Augment Clinical Decision-Making

Adam Moore^{1,2}, Gareth Jenkins², Savita Shanbhag³, Yeung Ng⁴, Emma Crawford², Reyer Zwiggelaar¹, Praboda Rajapaksha^{1,2}

1. Department of Computer Science, Aberystwyth University
2. Data Science, Hywel Dda University Health Board
3. Medical Directorate, Hywel Dda University Health Board
4. Urology, Hywel Dda University Health Board

Access to Vorasidenib for Low-Grade Glioma in the UK: Voices of Patients, Carers and Clinicians

Rachel Roberts¹, Shannon Winslade¹, Kiran Cheema¹, Anita Harries¹, Clare Jackson¹, Cameron Miller²

1. Support Team, The Brain Tumour Charity
2. Policy and Campaigns, The Brain Tumour Charity

Barriers to ovarian cancer risk reducing salpingectomy during caesarean section: a cross-sectional survey across Wales

Tamsin Mantel-Cooper¹, Hemant Maraj¹

1. Department of Obstetrics and Gynaecology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board

Lynch syndrome in Wales: insights from routine health data adapted for surveillance and screening

Robert Maddison^{1,2}, Ceri Williams¹, David Tucker¹, Suki Baynton¹, Sian Nisbet³, Mark Davies⁴, Alex Murray³, Llion Davies¹

1. Congenital Anomaly Register and Information Service, Public Health Wales, Capital Quarter 2, Tyndall Street, Cardiff, CF10 4BZ
2. Wales Gene Park, Cardiff University, Wales Genomic Health Centre, Cardiff Edge Life Sciences Park, Longwood Drive, Whitchurch, Cardiff, CF14 7YU
3. All-Wales Medical Genomics Service, Wales Genomic Health Centre, Cardiff Edge Life Sciences Park, Longwood Drive, Whitchurch, Cardiff, CF14 7YU
4. Singleton Hospital, Swansea Bay University Health Board, Sketty Lane, Sketty, Swansea, SA2 8QA, UK

A qualitative exploration of translation Toyota cultural principles to an NHS radiotherapy setting

Francesca Lewis¹, Nick Pearn², Nicholas Courtier³

1. Innovation, Velindre University NHS Trust
2. Toyota Lean Management Centre, Toyota Motor Manufacturing UK
3. School of Healthcare Sciences, Cardiff University

Exploring behaviours towards routine Carbapenemase Producing Organism (CPO) screening at a regional cancer centre in Wales

Joanne Simpson¹, Nicholas Courtier²

1. Infection Prevention & Control Nurse, Velindre Cancer Centre
2. School of Healthcare Sciences, Cardiff University

Safe skills transfer and mentorship: the all-wales colorectal peritoneal metastases service – a collaborative strategy to develop a new national service

Jody Parker¹, Matthew McKenna¹, Leigh Davies¹, Jared Torkington¹, Daniel Chung², Caroline Trezise¹, Tom Ceci³, Brenden Moran³

1. Department of Colorectal Surgery, Cardiff and Vale University Health Board
2. Department of Radiology, Cardiff and Vale University Health Board
3. Department of Colorectal Surgery, Hampshire Hospitals NHS Foundation Trust

Introduction of Expiratory Muscle Strength Training (EMST) for Head and Neck Cancer patients with chronic dysphagia post treatment.

Menna Payne¹, Kerry Davies¹, Lindsey Jose¹, Rebecca Mears¹

1. Speech and Language Therapy Department. Royal Glamorgan Hospital, Cwm Taf Morgannwg University Health Board

Improving the Speech and Language Therapy (SLT) rehabilitation pathway for patients with late effects dysphagia post head and neck cancer treatment

Menna Payne¹, Kerry Davies¹, Lindsey Jose¹, Rebecca Mears¹

1. Speech and Language Therapy Department. Royal Glamorgan Hospital, Cwm Taf Morgannwg University Health Board